Relationship of Cardiovascular Diseases and Bone Mineral Density in Postmenopausal Women

Document Type : Original Article (s)

Authors

1 Associate Professor, Department of Anatomical Sciences and Molecular Biology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

2 Assistant Professor, Department of Medical Physics, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

3 Student of Medicine, School of Medicine AND Student Research Committee, Isfahan University of Medical Sciences, Isfahan, Iran

4 Osteoporosis Diagnosis Center, Isfahan, Iran

Abstract

Background: Cardiovascular diseases and osteoporosis are two common chronic conditions particularly in elderly populations, which result in significant morbidity and mortality. Previous studies have shown the relationship of some sorts of heart disease and decrease in bone mineral density (BMD) and presence of osteoporosis. This study aimed to evaluate the relationship of cardiovascular diseases and osteoporosis in postmenopausal women.Methods: 200 patients with a mean age of 66.7 ± 5.8 years (range 52-79 years) were enrolled in this study. Patients were divided in two groups of with and without heart disease according to their medical records. Patients underwent dual-energy x-ray absorptiometry (DXA) measurements at hip and lumbar spines (L2, L3, and L4), greater trochanter, and femur neck. Results were showed as T-score and BMD in g/cm2. The patients were divided into three groups according to T-score (normal, osteopenic, and osteoporotic) after collecting the data, Chi-square (for qualitative variables), t (for quantitative variables), and the Mann-Whitney tests were used for data analysis.Findings: No significant difference was seen between subjects with and without heart disease in mean value of BMD. In addition, there was no statistical significant difference between these two groups in distribution of osteoporotic, osteopenic, and normal density subjects (P > 0.05) in various points of skeleto.Conclusion: In this study, no relationship was observed between cardiovascular disease (as a whole) and BMD and presence of osteoporosis.

Keywords

References

  1. Aluoch AO, Jessee R, Habal H, Garcia-Rosell M, Shah R, Reed G, et al. Heart failure as a risk factor for osteoporosis and fractures. Curr Osteoporos Rep 2012; 10(4): 258-69.
  2. Anagnostis P, Karagiannis A, Kakafika AI, Tziomalos K, Athyros VG, Mikhailidis DP. Atherosclerosis and osteoporosis: age-dependent degenerative processes or related entities? Osteoporos Int 2009; 20(2): 197-207.
  3. Anker SD, Clark AL, Teixeira MM, Hellewell PG, Coats AJ. Loss of bone mineral in patients with cachexia due to chronic heart failure. Am J Cardiol 1999; 83(4): 612-5, A10.
  4. Aung K, Htay T. Thiazide diuretics and the risk of hip fracture. Cochrane Database Syst Rev 2011; (10): CD005185.
  5. Bagger YZ, Rasmussen HB, Alexandersen P, Werge T, Christiansen C, Tanko LB. Links between cardiovascular disease and osteoporosis in postmenopausal women: serum lipids or atherosclerosis per se? Osteoporos Int 2007; 18(4): 505-12.
  6. Barasch E, Gottdiener JS, Aurigemma G, Kitzman DW, Han J, Kop WJ, et al. Association between elevated fibrosis markers and heart failure in the elderly: the cardiovascular health study. Circ Heart Fail 2009; 2(4): 303-10.
  7. Bello N, Mosca L. Epidemiology of coronary heart disease in women. Prog Cardiovasc Dis 2004; 46(4): 287-95.
  8. Abou-Raya S, Abou-Raya A. Osteoporosis and congestive heart failure (CHF) in the elderly patient: double disease burden. Arch Gerontol Geriatr 2009; 49(2): 250-4.
  9. Bozic B, Loncar G, Prodanovic N, Radojicic Z, Cvorovic V, Dimkovic S, et al. Relationship between high circulating adiponectin with bone mineral density and bone metabolism in elderly males with chronic heart failure. J Card Fail 2010; 16(4): 301-7.
  10. Brixner D. Assessment of the prevalence and costs of osteoporosis treatment options in a real-world setting. Am J Manag Care 2006; 12(7 Suppl): S191-S198.
  11. Bucay N, Sarosi I, Dunstan CR, Morony S, Tarpley J, Capparelli C, et al. Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev 1998; 12(9): 1260-8.
  12. Carbone L, Buzkova P, Fink HA, Lee JS, Chen Z, Ahmed A, et al. Hip fractures and heart failure: findings from the Cardiovascular Health Study. Eur Heart J 2010; 31(1): 77-84.
  13. Chhokar VS, Sun Y, Bhattacharya SK, Ahokas RA, Myers LK, Xing Z, et al. Loss of bone minerals and strength in rats with aldosteronism. Am J Physiol Heart Circ Physiol 2004; 287(5): H2023-H2026.
  14. Christenson ES, Jiang X, Kagan R, Schnatz P. Osteoporosis management in post-menopausal women. Minerva Ginecol 2012; 64(3): 181-94.
  15. Cummings SR, Ensrud K, Delmas PD, LaCroix AZ, Vukicevic S, Reid DM, et al. Lasofoxifene in postmenopausal women with osteoporosis. N Engl J Med 2010; 362(8): 686-96.
  16. Doherty TM, Fitzpatrick LA, Inoue D, Qiao JH, Fishbein MC, Detrano RC, et al. Molecular, endocrine, and genetic mechanisms of arterial calcification. Endocr Rev 2004; 25(4): 629-72.
  17. Hashemipour S, Larijani B, Adibi H, Javadi E, Sedaghat M, Pajouhi M, et al. Vitamin D deficiency and causative factors in the population of Tehran. BMC Public Health 2004; 4: 38.
  18. Hettiaratchy S, Papini R. Initial management of a major burn: II--assessment and resuscitation. BMJ 2004; 329(7457): 101-3.
  19. Holick MF. Vitamin D: important for prevention of osteoporosis, cardiovascular heart disease, type 1 diabetes, autoimmune diseases, and some cancers. South Med J 2005; 98(10): 1024-7.
  20. Hovsepian S, Amini M, Aminorroaya A, Amini P, Iraj B. Prevalence of vitamin D deficiency among adult population of Isfahan City, Iran. J Health Popul Nutr 2011; 29(2): 149-55.
  21. Jankowska EA, Jakubaszko J, Cwynar A, Majda J, Ponikowska B, Kustrzycka-Kratochwil D, et al. Bone mineral status and bone loss over time in men with chronic systolic heart failure and their clinical and hormonal determinants. Eur J Heart Fail 2009; 11(1): 28-38.
  22. Jordan KM, Cooper C. Epidemiology of osteoporosis. Best Pract Res Clin Rheumatol 2002; 16(5): 795-806.
  23. Jordan VC, Gapstur S, Morrow M. Selective estrogen receptor modulation and reduction in risk of breast cancer, osteoporosis, and coronary heart disease. J Natl Cancer Inst 2001; 93(19): 1449-57.
  24. Lee AH, Mull RL, Keenan GF, Callegari PE, Dalinka MK, Eisen HJ, et al. Osteoporosis and bone morbidity in cardiac transplant recipients. Am J Med 1994; 96(1): 35-41.
  25. Lim LS, Fink HA, Kuskowski MA, Taylor BC, Schousboe JT, Ensrud KE. Loop diuretic use and increased rates of hip bone loss in older men: the Osteoporotic Fractures in Men Study. Arch Intern Med 2008; 168(7): 735-40.
  26. Luo G, Ducy P, McKee MD, Pinero GJ, Loyer E, Behringer RR, et al. Spontaneous calcification of arteries and cartilage in mice lacking matrix GLA protein. Nature 1997; 386(6620): 78-81.
  27. Lynn H, Kwok T, Wong SY, Woo J, Leung PC. Angiotensin converting enzyme inhibitor use is associated with higher bone mineral density in elderly Chinese. Bone 2006; 38(4): 584-8.
  28. Mani A, Radhakrishnan J, Wang H, Mani A, Mani MA, Nelson-Williams C, et al. LRP6 mutation in a family with early coronary disease and metabolic risk factors. Science 2007; 315(5816): 1278-82.
  29. Min H, Morony S, Sarosi I, Dunstan CR, Capparelli C, Scully S, et al. Osteoprotegerin reverses osteoporosis by inhibiting endosteal osteoclasts and prevents vascular calcification by blocking a process resembling osteoclastogenesis. J Exp Med 2000; 192(4): 463-74.
  30. Nowicka G, Panczenko-Kresowska B. Coronary heart disease and osteoporosis: factors related to development of both diseases. Przegl Lek 2007; 64(3): 153-8.
  31. Schlienger RG, Meier CR. HMG-CoA reductase inhibitors in osteoporosis: do they reduce the risk of fracture? Drugs Aging 2003; 20(5): 321-36.
  32. Schocken DD, Arrieta MI, Leaverton PE, Ross EA. Prevalence and mortality rate of congestive heart failure in the United States. J Am Coll Cardiol 1992; 20(2): 301-6.
  33. Sosa M, Saavedra P, Gomez de Tejada MJ, Mosquera J, Perez-Cano R, Olmos JM, et al. Beta-blocker use is associated with fragility fractures in postmenopausal women with coronary heart disease. Aging Clin Exp Res 2011; 23(2): 112-7.
  34. Tintut Y, Parhami F, Tsingotjidou A, Tetradis S, Territo M, Demer LL. 8-Isoprostaglandin E2 enhances receptor-activated NFkappa B ligand (RANKL)-dependent osteoclastic potential of marrow hematopoietic precursors via the cAMP pathway. J Biol Chem 2002; 277(16): 14221-6.
  35. van DS, Majumdar SR, Bakal JA, McAlister FA, Ezekowitz JA. Heart failure is a risk factor for orthopedic fracture: a population-based analysis of 16,294 patients. Circulation 2008; 118(19): 1946-52.
Journal of Isfahan Medical School
Volume 31, Issue 271 - Serial Number 271
November and December 2014
Pages 2423-2433

Files

History

  • Receive Date: 23 November 2013
  • Revise Date: 01 November 2024
  • Accept Date: 06 April 2022

Share

How to cite

Statistics